Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between March 22 and March 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard E. Lowenthal, the President and CEO of ARS Pharmaceuticals, Inc. (SPRY), reported the sale of common stock between March 22 and March 25, 2024.
• The sales were conducted under a Rule 10b5-1 trading plan established on March 31, 2023.
• On March 22, 2024, 1,017 shares were sold at a weighted average price of $9.0298, with prices ranging from $9.00 to $9.06.
• Also on March 22, 2024, 1,326 shares were sold at a weighted average price of $9.0132, with prices ranging from $9.00 to $9.07.
• On March 25, 2024, 47,635 shares were sold at a weighted average price of $9.1238, with prices ranging from $9.03 to $9.36.
• Additionally on March 25, 2024, 47,632 shares were sold at a weighted average price of $9.1236, with prices ranging from $9.03 to $9.36.
• Following these transactions, Lowenthal directly owns 4,126,822 shares of common stock.
• Lowenthal also has indirect ownership through various trusts, including the Sarina Tanimoto Charitable Remainder UniTrust and the Lowenthal-Tanimoto Family Trust.
• The report indicates indirect ownership of 1,697,447 shares by Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 after the sales on March 25, 2024.
• The report indicates indirect ownership of 1,948,499 shares by Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 after the sales on March 25, 2024.
• Lowenthal also has indirect ownership of 1,696,494 shares by Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020.
• Lowenthal also has indirect ownership of 3,276,854 shares by spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sales were conducted under a pre-arranged 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and orderly way for insiders to sell shares.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Insider trading activity is closely monitored in the pharmaceutical industry, as it can provide insights into management's perspective on the company's prospects, especially concerning drug development and regulatory approvals.

Comparison to Industry Standards

• It is common for executives at publicly traded companies, including pharmaceutical firms like ARS Pharmaceuticals, to utilize 10b5-1 trading plans to diversify their holdings or manage personal finances.
• These plans are often adopted to avoid accusations of insider trading, as they are established in advance and operate independently of any material non-public information.
• Comparable companies such as Amgen, Gilead Sciences, and Pfizer also see regular Form 4 filings related to insider transactions.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates